# STAT+: Argenx to buy Forte Biosciences for $2.2B
Canonical URL: https://biopharmsignal.com/news/MARKET/stat-argenx-to-buy-forte-biosciences-for-2-2b-c328714f
Ticker: MARKET
Company: MARKET
Source: STAT News
Published: 2026-07-27 07:26 EST
Original Source URL: https://www.statnews.com/2026/07/27/argenx-acquire-forte-biosciences-autoimmune-diseases/?utm_campaign=rss
## Summary

Argenx plans to buy Forte Biosciences for $2.2 billion, expanding its pipeline of drugs that could treat multiple autoimmune diseases.

## Article Body
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

Argenx said Monday it would buy Forte Biosciences to expand its immunology pipeline, continuing the sector’s acquisition run , as even midsize companies hunt for pick-up targets.

The deal, worth $2.2 billion in cash, values Dallas-based Forte at $77 per share, a 41% premium to the biotech’s closing price on Friday.

Argenx, which has its main operations in Belgium, has become a top success story in immunology. Its drug Vyvgart, approved to treat the autoimmune diseases generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, has delivered steady sales increases as its label has been widened to cover more patients.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe
## Recent Company News
- 2026-07-27 08:30 EST — [Opinion: How midwives like me can help fight medical misinformation](https://biopharmsignal.com/news/MARKET/opinion-how-midwives-like-me-can-help-fight-medical-misinformation-8ad871ca) — Source: STAT News
- 2026-07-27 08:30 EST — [STAT+: As some medical schools embrace RFK Jr.’s nutrition push, they deftly sidestep MAHA priorities](https://biopharmsignal.com/news/MARKET/stat-as-some-medical-schools-embrace-rfk-jr-8217-s-nutrition-push-they-deftly-si-00df11eb) — Source: STAT News
- 2026-07-27 08:30 EST — [Opinion: E-bikes, e-scooters are a burgeoning pediatric public health emergency](https://biopharmsignal.com/news/MARKET/opinion-e-bikes-e-scooters-are-a-burgeoning-pediatric-public-health-emergency-546b4960) — Source: STAT News
- 2026-07-27 07:26 EST — [STAT+: Argenx to buy Forte Biosciences for $2.2B](https://biopharmsignal.com/news/MARKET/stat-argenx-to-buy-forte-biosciences-for-2-2b-c328714f) — Source: STAT News
## Related News
- 2026-07-27 08:30 EST — MARKET — [Opinion: How midwives like me can help fight medical misinformation](https://biopharmsignal.com/news/MARKET/opinion-how-midwives-like-me-can-help-fight-medical-misinformation-8ad871ca)
- 2026-07-27 08:30 EST — MARKET — [STAT+: As some medical schools embrace RFK Jr.’s nutrition push, they deftly sidestep MAHA priorities](https://biopharmsignal.com/news/MARKET/stat-as-some-medical-schools-embrace-rfk-jr-8217-s-nutrition-push-they-deftly-si-00df11eb)
- 2026-07-27 08:30 EST — MARKET — [Opinion: E-bikes, e-scooters are a burgeoning pediatric public health emergency](https://biopharmsignal.com/news/MARKET/opinion-e-bikes-e-scooters-are-a-burgeoning-pediatric-public-health-emergency-546b4960)
- 2026-07-24 20:01 EST — BRKR — [Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast](https://biopharmsignal.com/news/BRKR/bruker-announces-date-and-time-of-second-quarter-2026-earnings-release-and-webca-29470a21)
- 2026-07-24 12:00 EST — NAMS — [NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-and-menarini-group-receive-positive-chmp-opinion-recommendin-6e39bfc3)